Abstract
Terguride, a partial DA-agonist with both dopaminergic and antidopaminergic properties, was tested in 11 PD patients in the “decompensated” phase of the disease, characterized by the presence of dyskinesias and motor fluctuations. Combined treatment of these patients with 1 mg/day of terguride and stabilized doses of levodopa reduced the severity and frequency of dyskinesias and motor fluctuations along with a slight but significant improvement of parkinsonian clinical picture. The “modulatory” effect of terguride on DA receptors, in this experimental conditions, is discussed.
Sommario
La terguride, DA agonista parziale con proprietà contemporaneamente dopaminergiche ed antidopaminergiche, è stata valutata in 11 pazienti parkinsoniani in fase “decompensata” di evoluzione di malattia, caratterizzata da discinesie e fluttuazioni motorie. Il trattamento combinato di questi pazienti con terguride alla dose di 1 mg/die e levodopa a dosi stabilizzate, ha ridotto la gravità e la frequenza delle discinesie, determinando contemporaneamente un lieve ma significativo miglioramento del quadro parkinsoniano. Viene discusso l'effetto “modulatorio” della terguride sui recettori dopaminergici, in questa condizione sperimentale.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bassi S., Albizzati M.G., Corsini G.U., Frattola L., Piolti R., Suchy I., Trabucchi M.:Therapeutic experience with transdihydrolisuride in Huntington's disease. Neurology 36:984–986, 1986.
Brucke T., Danielczyk W., Simanyi M., Sofic E., Riederer P.:Terguride partial dopamine agonist in the treatment of Parkinson's Disease. In: Yahr MD and Bergmann KJ, eds. Advances in Neurology (Vol. 45), New York: Raven Press, 573–576, 1986.
Calne D.B., Stoessl A.J.:Transmitter receptor alterations in Parkinson's disease. In: Yahr MD and Bergmann JK, eds. Advances in Neurology (Vol. 45, New York: Raven Press, 45–49, 1986.
Carlsson A.:Dopamine receptor agonist: intrinsic activity vs. state of receptor. J. Neural Transm. 57:309–315, 1983.
Corsini G.U., Horowski R., Rainer, E., Del Zompo M.:Treatment of Parkinson's disease with a dopamine partial agonist. Clin. Neuropharmacol. 7(1),515, 1984.
Corsini G.U., Bonnucelli U., Rainer E., Del Zompo M.:Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. J. Neural Transm, 64:105–11, 1985.
Critchley P., Parkes D.:Transdihydrolisuride in Parkinsonian. Clinical Neuropharmacology, 10:57–64, 1987.
Groppetti A., Flauto C., Parati E., Vesovi A., Rusconi L., Parenti M.:Dopamine receptor changes in response to prolonged treatment with L-dopa. J. Neural Transm, (Suppl) 22:33–45, 1986.
Guttman M., Seeman P.:Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age and duration of l-dopa therapy. In: Yahr MD and Bergmann KJ, eds. Advances in Neurology (Vol. 45), New York: Raven Press, 51–57, 1986.
Kehr W., Wachtel H., Schneider H.H.:Dopaminergic and antidopaminergic properties of ergolines structurally related to lisuride. In: Carlsson A., Nilsson G., eds. Dopamine Receptor Agonist Proceedings 2, Acta Pharm. Suec. (Suppl. 2):98–100, 1983.
Kehr W.:Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism. Europ. J. Pharmacol. 97:111–119, 1984.
Rinne U.K.:Brain neurotransmitter receptors in Parkinson's disease. In: Marsden CD, Fahn S., eds. Neurology 2: Movement Disorders. London: Butterworths, 59–74, 1982.
Suchy I., Schneider H.H., Rieder P., Horowsky R.:Considerations on the clinical relevance of differences in receptor affinity of various dopaminergic ergot alkaloids. Psychopharmacol. Bull 19:743–746, 1983.
Suchy I., Rinne U.K., Wachtel H.:Evaluation of terguride in patients with Parkinson's Disease. In: Yahr MD and Bergmann K.J., eds. Advances in Neurology (Vol. 45), New York: Raven Press, 577–581, 1986.
Wachtel H., Rettig K.J., Seltz A.:The central dopamine agonist action of transdihydrolisuride is unmasked at supersensitive receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 325:R80, 1984.
Wachtel H.:Central dopaminergic and antidopaminergic effects of ergot derivates structurally related to lisuride. In: Calne DB, R. Horowsky, McDonald R.J., Wuttke W., eds. Lisuride and other Donamine Agonist. New York: Raven Press, 109–125, 1983.
Wachtel H., Dorow R.:Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci. 32:421–432, 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giovannini, P., Piccolo, I., Genitrini, S. et al. Terguride in the treatment of Parkinson disease: preliminary experience. Ital J Neuro Sci 11, 381–385 (1990). https://doi.org/10.1007/BF02335941
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02335941